Clinical Endpoints at 3- and 6-Month Follow-up
| Follow-up interval | Study patients | Controls | P |
| 3 mo | |||
| Total | 115 | 230 | |
| Cure | 72 (62.6) | 151 (65.6) | 0.63 |
| Relapse | 3 (2.6) | 17 (7.4) | 0.09 |
| Persisting infection | 21 (18.2) | 3 (1.3) | 0.001 |
| Mortality | 19 (16.6) | 59 (25.7) | 0.06 |
| Relapse in S. aureus subgroup | 1/73 (1.4) | 13/146 (8.9) | 0.04 |
| 6 mo* | |||
| Total | 115 | 230 | |
| Cure | 83 (72.2) | 154 (66.9) | 0.26 |
| Persisting infection | 8 (7) | 0 | <0.001 |
| Overall mortality | 22 (19.1) | 74 (32.2) | 0.007 |
| Infection-related mortality | 17 (14.8) | 56 (24.3) | 0.049 |
| Lost to follow-up | 2 (1.7) | 2 (0.9) | 0.60 |
↵* At 6-mo follow-up, 8 patients had died after relapse of infection in control group vs. 2 in study group.
Data presented in parentheses are percentages. P values are estimated by Fisher exact tests.